{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:12:10Z","timestamp":1784344330621,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"vor","delay-in-days":1140,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.repc.2015.09.009","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T13:15:22Z","timestamp":1456665322000},"page":"141-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Consequ\u00eancias cl\u00ednicas e econ\u00f3micas da utiliza\u00e7\u00e3o de dabigatrano e de rivaroxabano em doentes com fibrilha\u00e7\u00e3o auricular n\u00e3o valvular"],"prefix":"10.1016","volume":"35","author":[{"given":"Lu\u00eds","family":"Silva Miguel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2015.09.009_bib0130","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","article-title":"Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population\u2010based study","volume":"36","author":"Marini","year":"2005","journal-title":"Stroke."},{"key":"10.1016\/j.repc.2015.09.009_bib0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/STROKEAHA.108.516344","article-title":"Potentially preventable strokes in high\u2010risk patients with atrial fibrillation who are not adequately anticoagulated","volume":"40","author":"Gladstone","year":"2009","journal-title":"Stroke."},{"key":"10.1016\/j.repc.2015.09.009_bib0140","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1212\/01.wnl.0000326895.58992.27","article-title":"Warfarin use leads to larger intracerebral hematomas","volume":"71","author":"Flaherty","year":"2008","journal-title":"Neurology."},{"key":"10.1016\/j.repc.2015.09.009_bib0145","first-page":"331","article-title":"Preval\u00eancia de fibrilha\u00e7\u00e3o auricular na popula\u00e7\u00e3o portuguesa com 40 ou mais anos \u2013 Estudo FAMA","volume":"29","author":"Bonhorst","year":"2010","journal-title":"Rev Port Cardiol."},{"key":"10.1016\/j.repc.2015.09.009_bib0150","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC Member Countries \u2013 The Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2015.09.009_bib0155","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta\u2010analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.repc.2015.09.009_bib0160","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connoly","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2015.09.009_bib0165","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE\u2010LY trial","volume":"363","author":"Connoly","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2015.09.009_bib0170","unstructured":"EMA (2011). Resumo do EPAR destinado ao p\u00fablico [acessado em 15 de junho de 2015]. Dispon\u00edvel em: http:\/\/www.ema.europa.eu\/docs\/pt_PT\/document_library\/EPAR_\u2010_Summary_for_the_public\/human\/000829\/WC500041060.pdf."},{"key":"10.1016\/j.repc.2015.09.009_bib0175","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2015.09.009_bib0180","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2015.09.009_bib0185","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.repc.2013.01.005","article-title":"Avalia\u00e7\u00e3o econ\u00f3mica do dabigatrano na preven\u00e7\u00e3o de acidentes vasculares cerebrais isqu\u00e9micos em doentes com fibrilha\u00e7\u00e3o auricular n\u00e3o valvular","volume":"32","author":"Miguel","year":"2013","journal-title":"Rev Port Cardiol."},{"key":"10.1016\/j.repc.2015.09.009_bib0190","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.repc.2014.02.020","article-title":"Estudo de custo\u2010efectividade de rivaroxabano para preven\u00e7\u00e3o de acidente vascular cerebral em doentes com fibrilha\u00e7\u00e3o auricular em Portugal","volume":"33","author":"Morais","year":"2014","journal-title":"Rev Port Cardiol."},{"key":"10.1016\/j.repc.2015.09.009_bib0195","unstructured":"IMS Health, IMS MIDAS 2014."},{"key":"10.1016\/j.repc.2015.09.009_bib0200","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1160\/TH11-02-0089","article-title":"Cost\u2010effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective","volume":"105","author":"Sorensen","year":"2011","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.repc.2015.09.009_bib0205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/heartjnl-2011-300646","article-title":"Cost\u2010effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation","volume":"98","author":"Kansal","year":"2012","journal-title":"Heart."},{"key":"10.1016\/j.repc.2015.09.009_bib0210","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect\u2010treatment\u2010comparison and network\u2010meta\u2010analysis studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practice \u2013 Part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health."},{"key":"10.1016\/j.repc.2015.09.009_bib0215","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta\u2010analysis for health\u2010care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health."},{"key":"10.1016\/j.repc.2015.09.009_bib0220","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1160\/TH12-06-0388","article-title":"Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost\u2010effectiveness","volume":"108","author":"Kansal","year":"2012","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.repc.2015.09.009_bib0225","unstructured":"FDA (2011). FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) [acessado em 15 de junho de 2015]. Dispon\u00edvel em: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/ucm270796.pdf."},{"key":"10.1016\/j.repc.2015.09.009_bib0230","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00019053-200321030-00004","article-title":"A meta\u2010analysis of quality\u2010of\u2010life estimates for stroke","volume":"21","author":"Tengs","year":"2003","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.repc.2015.09.009_bib0235","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/00019053-200624100-00009","article-title":"The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US","volume":"24","author":"Sullivan","year":"2006","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.repc.2015.09.009_bib0240","article-title":"Orienta\u00e7\u00f5es metodol\u00f3gicas para estudos de avalia\u00e7\u00e3o econ\u00f3mica de medicamentos","author":"Silva","year":"1998","journal-title":"INFARMED"},{"key":"10.1016\/j.repc.2015.09.009_bib0245","unstructured":"CADTH. Safety, Effectiveness, and Cost\u2010Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. CADTH, 2012; Ottawa."},{"key":"10.1016\/j.repc.2015.09.009_bib0250","series-title":"European Cardiovascular Disease Statistics","author":"Nichols","year":"2012"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"pt","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255115003182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255115003182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:03:32Z","timestamp":1760108612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255115003182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0870255115003182"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2015.09.009","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consequ\u00eancias cl\u00ednicas e econ\u00f3micas da utiliza\u00e7\u00e3o de dabigatrano e de rivaroxabano em doentes com fibrilha\u00e7\u00e3o auricular n\u00e3o valvular","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2015.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}